Asthma | Unmet Need | Detailed, Expanded Analysis (Severe Asthma)

Publish date: April 2019

Login to access report


Several effective anti-inflammatory agents and bronchodilators are available for controlling patients’ mild or moderate asthma. However, despite the market entry of LAMAs (e.g., Boehringer Ingelheim’s Spiriva) and novel biologics (e.g., AstraZeneca’s Fasenra, Sanofi/Regeneron’s Dupixent), an unmet need remains for effective therapies for severe disease, especially for patients whose symptoms are not adequately controlled with current therapies or who depend on frequent SABA or oral corticosteroid use to achieve relief. This Unmet Need report provides quantitative insight into key treatment drivers and goals and the current level of unmet need in severe asthma based on the perceptions of U.S. and European physicians. We analyze the commercial opportunities and how emerging therapies could capitalize on these opportunities.


  • What are the treatment drivers and goals for severe asthma?
  • What attributes are key influencers, which have limited impact, and which are hidden opportunities?
  • How do current inhaled agents (e.g., Spiriva) and biological therapies (e.g., Dupixent, GSK’s Nucala) perform on key treatment drivers and goals in severe asthma?
  • What are the prevailing areas of unmet need and opportunity in severe asthma?
  • What trade-offs across different clinical attributes and prices are acceptable to U.S. and European physicians for a hypothetical new drug targeting severe asthma?


Provides quantitative insight into U.S. and European physician perceptions of key treatment drivers and goals and the current level of unmet need for a specific disease. Commercial opportunities are analyzed, and the extent to which emerging therapies may capitalize on these opportunities is evaluated.

Markets covered: United States, United Kingdom, France, Germany.

Primary research: Survey of approximately 30 U.S. pulmonologists, 30 U.S. allergists, and 30 European pulmonologists.

Key companies: Roche, Novartis, GlaxoSmithKline, Teva, AstraZeneca, Regeneron, Sanofi, Boehringer Ingelheim.

Key drugs: Xolair, Nucala, Cinqair/Cinqaero, Fasenra, Dupixent, Spiriva (tiotropium).

Table of contents

  • Detailed, Expanded Analysis (Severe Asthma)
    • Introduction
      • Overview
      • Methodology
      • Rationale for Treatment Drivers and Goals Selection
        • Efficacy
        • Safety and Tolerability
        • Convenience of Administration
        • Nonclinical Factors
      • Rationale for Drug Selection
    • Treatment Drivers and Goals
      • Key Findings: Attribute Importance
      • Key Findings: Stated vs. Derived Importance
    • Product Performance Against Treatment Drivers and Goals
      • Key Findings
    • Assessment of Unmet Need
      • Key Findings: Unmet Need in Severe Asthma
      • Key Findings: Unmet Need in Severe Asthma and Related Indications
    • Opportunity Analysis
      • Areas of Opportunity in the Severe Asthma Market and Emerging Therapy Insights
        • Opportunity: Treatments with Robust Efficacy in Reducing Exacerbation Rates
        • Opportunity: Treatments Offering Less Burdensome Administration
        • Opportunity: Treatments with Demonstrated Efficacy in Patients with TH2-Low Asthma
    • Target Product Profiles
      • Assessing Drug Development Opportunities
      • Target Product Profile Methodology
      • Attribute Importance and Part-Worth Utilities
        • Severe Asthma Target Product Profile: Attribute-Level Part-Worth Utilities
      • Conjoint Analysis-Based Simulations of Market Scenarios
        • Scenario 1
        • Scenario 2
    • Appendix
      • Experts Interviewed
      • Bibliography

Author(s): Shubhendu Ghosh, PhD

Shubhendu Ghosh, is a Business Insights Analyst on the Immune and Inflammatory Disorders team at Decision Resources Group, with a primary focus on asthma. Prior to joining DRG, Shubhendu was an Associate Editor at Nature Structural & Molecular Biology and a Copy Editor at Nature Medicine. He was also a Scientific and Developmental Editor at Nature Research Editing Service. Shubhendu received his in Biomedical Sciences from the University of Massachusetts Medical School after completing a B. Sc. in Microbiology from Delhi University and an M. Sc. In Biotechnology from Madurai Kamaraj University.